GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WPD Pharmaceuticals Inc (XCNQ:WBIO) » Definitions » EBIT

WPD Pharmaceuticals (XCNQ:WBIO) EBIT : C$6.02 Mil (TTM As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is WPD Pharmaceuticals EBIT?

WPD Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was C$0.00 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was C$6.02 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. WPD Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2023 was 0.00%. WPD Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. WPD Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 126.11%.


WPD Pharmaceuticals EBIT Historical Data

The historical data trend for WPD Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WPD Pharmaceuticals EBIT Chart

WPD Pharmaceuticals Annual Data
Trend Jan13 Jan14 Jan15 Jan16 Jan17 Jan18 Jan19 Dec20 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.38 -0.78 - 4.03 -

WPD Pharmaceuticals Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.20 -0.04 -0.07 -0.07 -

Competitive Comparison of WPD Pharmaceuticals's EBIT

For the Biotechnology subindustry, WPD Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


WPD Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WPD Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where WPD Pharmaceuticals's EV-to-EBIT falls into.



WPD Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$6.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WPD Pharmaceuticals  (XCNQ:WBIO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

WPD Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=0 * ( 1 - 0% )/( (0 + 0.224)/ 2 )
=0/0.112
=0.00 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

WPD Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0/( ( (0 + max(-0.59, 0)) + (0 + max(-0.595, 0)) )/ 2 )
=0/( ( 0 + 0 )/ 2 )
=0/0
= %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.012) - (0.602 + 0 + 0)
=-0.59

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.003) - (0.598 + 0 + 0)
=-0.595

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

WPD Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=6.019/4.773
=126.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WPD Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of WPD Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


WPD Pharmaceuticals (XCNQ:WBIO) Business Description

Traded in Other Exchanges
N/A
Address
750 West Pender Street, Suite 401, Vancouver, BC, CAN, V6C 2T7
WPD Pharmaceuticals Inc is a biotechnology research and development company. It focuses on oncology, research, and development of medicinal products involving biological compounds and small molecules. The company has eight novel drug candidates which are in clinical development and pre-clinical development stage.

WPD Pharmaceuticals (XCNQ:WBIO) Headlines

No Headlines